Euphora Semi-Compliant Rapid Exchange Balloon Dilatation Catheter 의 안전성 경고

Department of Health에 따르면, 해당 안전성 경고 는 Hong Kong 에서 Medtronic 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

안전성 경고는 의료기기 제품과 관련된 중요한 정보와 권고사항을 담고 있습니다. 물론 안전성 경고가 배포되었다고 해서 해당 제품이 무조건 안전하지 않은 제품이라는 것은 아닙니다. 보건의료업계 종사자와 의료기기 사용자들에게 배포되는 안전성 경고에는 회수(recall)도 포함될 수 있습니다. 제조사가 안전성 경고를 작성하기도 하지만, 보건당국에서 작성하는 경우도 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Safety alert
  • 날짜
    2017-07-14
  • 사례 출판 날짜
    2017-07-14
  • 사례 국가
  • 사례 출처
    DH
  • 사례 출처 URL
  • 비고 / 경고
    Hong Kong data is current through September 2018. All of the data comes from the Department of Health (Hong Kong), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Hong Kong.
  • 데이터 추가 비고
    Medical Device Safety Alert
  • 원인
    Medical device safety alert: medtronic euphora semi-compliant rapid exchange balloon dilatation catheter medical device manufacturer, medtronic, has issued a medical device safety alert concerning its euphora semi-compliant rapid exchange (rx) balloon dilatation catheter. the affected devices are identified as follows:- model numbers: eup1506x, eup1510x, eup1512x, eup1515x, eup1520x, eup2006x, eup2010x, eup2012x, eup2015x, eup2020x, eup2025x, eup2030x, eup22506x, eup22510x, eup22512x, eup22515x, eup22520x, eup22525x, eup2506x, eup2510x, eup2512x, eup2515x, eup2520x, eup2525x, eup2530x, eup27506x, eup27510x, eup27512x, eup27515x, eup27520x, eup27525x, eup3006x, eup3010x, eup3012x, eup3015x, eup3020x, eup3025x, eup3030x, eup32506x, eup32510x, eup32512x, eup32515x, eup32520x, eup32525x, eup3506x, eup3510x, eup3512x, eup3515x, eup3520x, eup3525x, eup3530x, eup37506x, eup37510x, eup37512x, eup37515x, eup37520x, eup37525x, eup4006x, eup4010x, eup4012x, eup4015x, eup4020x, eup4025x, eup4030x lot number: 212553130 to 213283557 expiration date: 4 january 2019 to 9 may 2019 the manufacturer has initiated a voluntarily recall of select lot numbers of the medtronic euphora semi-compliant rx balloon dilatation catheter due to reports of difficulties in removing the stylette. in the event, there is the potential for damage to the balloon or catheter due to excessive force being applied, and this may lead to balloon inflation or deflation challenges. potential risks include prolonged procedure time and the need for additional intervention. in addition, inflation or deflation difficulties or catheter damage during procedural use could result in vessel occlusion or injury. according to the manufacturer, they have received one report of patient injury related to this matter. as the issue is experienced at the time of product use, there is no additional action related to the recall for patients who have previously been treated with potentially affected product. the patients should continue to be monitored in accordance with the facility’s standard care protocols. the medtronic nc euphora non-compliant rx balloon dilatation catheters are not affected by the issue. the affected users are advised to immediately stop using devices from the affected lots and return all unused products to the manufacturer for replacement. according to the local supplier, the affected products are distributed in hong kong if you are in possession of the affected products, please contact your supplier for necessary actions. posted on 14 july 2017.

Device

  • 모델명 / 제조번호(시리얼번호)
  • 제품 설명
    Medical Device Safety Alert: Euphora Semi-Compliant Rapid Exchange Balloon Dilatation Catheter
  • Manufacturer

Manufacturer

  • 제조사 모회사 (2017)
  • 제조사 의견
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    DH